China Medical City (CMC), located in Taizhou City, an important member of the Yangtze River Delta, with a total planned area of 30 square kilometers, consisting of the scientific research and development area, the exhibition and trade area, the health and medical area, the education and teaching area and the comprehensive supporting area, is China's first national medical high-tech zone jointly built by the Ministry of Science and Technology, National Health and Family Planning Commission, China Food and Drug Administration, State Administration of Traditional Chinese Medicine and Jiangsu Provincial People's Government.
Since its inception and construction, CMC has been committed to creating China's largest and most comprehensive bio-medical industry base in line with the concept of "revitalizing city with industry, promoting industry with city, integrating city and industry, and achieving mutual prosperity of industry and city". CMC has so far gathered more than 60 domestic and foreign famous universities and medical R&D institutions, as well as nearly 800 domestic and foreign well-known pharmaceutical companies including Nestlé, AstraZeneca, Takeda Pharmaceutical, Boehringer-Ingelheim, CSPC Pharmaceutical Group and Neptunus Pharmaceutical, declared more than 1,000 "domestic-leading international" pharmaceutical innovation results, attracted more than 2,800 high-level talents at home and abroad, among whom 43 have been enlisted in the national "Recruitment Program of Global Experts". In addition, CMC has been listed as a pilot city of the national new vaccine and specific diagnostic reagent industry cluster. Currently, an area of 16 square meters is under development.
The 13th Five-Year Plan period is a key period of construction and development for CMC. CMC will improve the ministerial and provincial co-construction mechanism by highlighting "medical" and "medicine" in line with the 13th Five-Year Plan, and primarily promote industrial agglomeration by seizing the strategic opportunity of "healthy China" based on the pilot agglomeration and development of the big health industry in the Taizhou Yangtze River Economic Belt in order to comprehensively enhance the overall strength, introduce 1,000 pharmaceutical enterprises by 2019, create a RMB 100 billion pharmaceutical industry, achieve "two ten-year goals", establish the national leading position of Taizhou's biotechnology and new medical industry and become an industrial cluster, an innovative cluster and a talent cluster for the global bio-medical industry.
Investment consulting hotline: (domestic) 0523-86200055（18036781212）；0523-86200000；18762345048 ；(international) 0523-86200007；+86-15852977958；0523-86200142；+86-18262307755